Extractables and Leachables (E&L) Testing vs. Drug-Device Compatibility Studies: What Is the Difference?
Introduction: E&L testing vs drug device compatibility studies comes down to one core distinction: E&L testing asks what chemicals migrate […]
What Is the Difference Between a Nitrosamine Screening Method and a Confirmatory Method?
Introduction The critical operational and compliance difference between a nitrosamine screening method and a confirmatory method is primarily defined by
What Is the Difference Between a Nitrosamine Screening Method and a Confirmatory Method? Read More »
What Is the Difference Between PLGA 50:50 and PLGA 75:25? How the LA:GA Ratio Affects Degradation and Release
Introduction The primary biophysical distinction between PLGA 50:50 and PLGA 75:25 is defined by their monomer composition, specifically the ratio
ICH M7 vs. FDA Nitrosamine Guidance: Regulatory Framework Alignment and Key Differences
Introduction: When comparing ICH M7 vs FDA Nitrosamine Guidance, both share the same objective — protecting patients from potentially carcinogenic
ICH M7 vs. FDA Nitrosamine Guidance: Regulatory Framework Alignment and Key Differences Read More »
PLGA for Vaccine and Antigen Delivery: Adjuvant Properties, Encapsulation Strategies, and Immune Response
Introduction Poly(lactic-co-glycolic acid) (PLGA)-based particulate delivery systems offer a highly biocompatible and biodegradable platform for protecting fragile biomolecules while enabling
Reversed-Phase HPLC Method Development for Therapeutic Peptide Purity and Impurity Profiling
Introduction Developing and implementing a scientifically optimized Reversed-Phase HPLC Method Development strategy is a fundamental analytical requirement for accurately determining
Generic Drug vs Biosimilar: What Is the Difference and How Does CDMO Support Differ?
Introduction The distinction between a Generic Drug vs Biosimilar forms the core scientific and regulatory boundary separating chemically synthesized small-molecule
Generic Drug vs Biosimilar: What Is the Difference and How Does CDMO Support Differ? Read More »
CMC Strategy for Complex Generic Injectables: What a CDMO Should Deliver
Introduction: A robust CMC Strategy for Complex Generic Injectables is one of the most important factors influencing successful ANDA approval.
CMC Strategy for Complex Generic Injectables: What a CDMO Should Deliver Read More »
Generic Drug Development for Poorly Soluble APIs: CDMO Approaches Using ASD, Nano, and Lipid Systems
Introduction Generic Drug Development for Poorly Soluble APIs requires advanced Contract Development and Manufacturing Organization (CDMO) strategies to address the
GMP Extractables and Leachables Testing: A Complete Guide for Drug Product Teams
Introduction Establishing a validated GMP Extractables and Leachables Testing program is an essential aspect of modern pharmaceutical development. It ensures
GMP Extractables and Leachables Testing: A Complete Guide for Drug Product Teams Read More »